BARDET-BIEDL SYNDROME

Bardet-Biedl Syndrome — a ciliopathy where the first FDA-approved genetic obesity therapy (setmelanotide) targets the specific melanocortin pathway disruption, requiring molecular BBS diagnosis for prescribing eligibility.

Whole genome sequencing evaluates all 25+ BBS genes simultaneously — including oligogenic and triallelic inheritance patterns that single-gene testing cannot detect — providing the molecular diagnosis required for setmelanotide therapy.

BBS1
BBS10
BBS2

About this condition

Bardet-Biedl Syndrome

Bardet-Biedl syndrome (BBS) is an autosomal recessive ciliopathy — a disorder of primary cilia, the sensory organelles present on virtually all cell types — caused by pathogenic variants in at least 25 genes (BBS1 through BBS21, plus additional modifiers). Primary cilia dysfunction disrupts signaling in multiple tissues, producing the characteristic BBS phenotype: retinal dystrophy (rod-cone dystrophy leading to blindness by the second decade), obesity (hyperphagia-driven, beginning in early childhood), renal anomalies (structural malformations, renal failure), postaxial polydactyly, learning disability, and hypogonadism. BBS affects approximately 1 in 100,000 in European populations, with higher prevalence in consanguineous populations.

The obesity in BBS is mechanistically distinct from common obesity — it is driven by disruption of leptin-melanocortin signaling in the hypothalamus, a direct consequence of ciliary dysfunction in hypothalamic neurons. This molecular mechanism is therapeutic target: setmelanotide (Imcivree), an MC4R agonist, was FDA-approved in 2022 for chronic weight management in patients with BBS aged 6 years and older. Setmelanotide produces clinically meaningful weight loss by bypassing the ciliary signaling defect and directly activating the downstream melanocortin-4 receptor pathway.

BBS exhibits genetic complexity beyond simple autosomal recessive inheritance. Oligogenic and triallelic inheritance — where variants in a second BBS gene modify disease severity or are required for full phenotypic expression — have been documented. BBS1 (p.Met390Arg) and BBS10 variants are the most common in European populations. The 25+ gene landscape and oligogenic modifier effects make comprehensive genomic testing essential — sequential single-gene testing is impractical, and gene panels may not include all known BBS genes or detect the modifier alleles that affect clinical expression.

Setmelanotide (Imcivree, FDA 2022) is the first therapy targeting the specific melanocortin pathway disruption in BBS obesity. Molecular BBS diagnosis is required for prescribing — standard obesity management does not address the underlying mechanism.

Gene locus: BBS1 (11q13.2), BBS10 (12q21.2), BBS2 (16q13), plus 22+ additional genes

25+ BBS genes with oligogenic inheritance cannot be evaluated by standard single-gene or small-panel testing. WGS captures the complete BBS genetic architecture including modifier alleles.

Setmelanotide prescribing requires confirmed BBS molecular diagnosis — empirical obesity management fails in BBS

Standard behavioral and pharmacological obesity interventions are largely ineffective in BBS because the obesity is driven by hypothalamic ciliary dysfunction, not by behavioral or metabolic factors amenable to conventional approaches. Setmelanotide specifically addresses this mechanism by activating MC4R downstream of the ciliary defect. The FDA indication specifies BBS confirmed by genetic testing. Without molecular diagnosis, BBS patients are managed with standard obesity interventions that address the wrong mechanism, while the targeted therapy remains unavailable.

Retinal dystrophy in BBS begins in childhood and progresses to blindness — early diagnosis enables low-vision preparation and future gene therapy eligibility

Rod-cone dystrophy in BBS typically progresses to legal blindness by the late teenage years or early twenties. Early molecular BBS diagnosis enables: immediate ophthalmological baseline and monitoring, low-vision skill development while residual vision remains, orientation and mobility training, and potential eligibility for emerging retinal gene therapy clinical trials that target specific BBS genes. Without early diagnosis, vision loss may be attributed to other causes, delaying the supportive interventions that maximize quality of life during the vision loss transition.

Bardet-Biedl Syndrome — a ciliopathy where the first FDA-approved genetic obesity therapy (setmelanotide) targets the specific melanocortin pathway disruption, requiring molecular BBS diagnosis for prescribing eligibility.

Bardet-Biedl Syndrome

25+ BBS genes with oligogenic inheritance cannot be evaluated by standard single-gene or small-panel testing. WGS captures the complete BBS genetic architecture including modifier alleles.

Setmelanotide prescribing requires confirmed BBS molecular diagnosis — empirical obesity management fails in BBS

Retinal dystrophy in BBS begins in childhood and progresses to blindness — early diagnosis enables low-vision preparation and future gene therapy eligibility

Others in Rare Diseases

One test. A lifetime of answers.